This clarification of the mechanisms underlying RA pathogenesis highlights resistin as a therapeutic target in RA and is confirmed by an investigation into resistin gene expression in pathogenetic leukocyte subsets from patients with active RA treated with TNF-α inhibitor therapy (adalimumab) for 3 months [79]. The gene discussed is RETN; the disease is rheumatoid arthritis.